Skip to search boxSkip to navigationSkip to main content

Nicotinamide treatment reduces behavioral impairments and provides cortical protection after fluid percussion injury in the rat

  • Michael R. Hoane(corresponding author)
    ,
  • Arlene A. Tan
    ,
  • Jeremy L. Pierce
    ,
  • Gail D. Anderson
    ,
  • Douglas C. Smith
*Corresponding author for this work
  • Southern Illinois University
    ,
  • University of Washington
Scholary Output:
Contribution to journal
Article
Peer-review

Abstract

This study examined the ability of nicotinamide (vitamin B3) to improve functional outcome in a dose-dependent manner following fluid percussion injury (FPI). Injured (duration of unconsciousness mean = 85.8 sec; apnea = 9.9 sec), rats were administered nicotinamide (500 or 50 mg/kg; ip) or saline at 15 min and 24 h. Serum analysis of nicotinamide concentrations were conducted 1 h following the last injection. Sensorimotor and cognitive tests were conducted for 35 days following FPI. Both the 500 and 50 mg/kg doses of nicotinamide significantly facilitated recovery on the vibrissae-forelimb placing test compared to saline treatment, which showed chronic impairments. Both treatments also significantly improved performance on the bilateral tactile adhesive removal test. On the cognitive tests, the 500 mg/kg dose, but not the 50 mg/kg dose, improved performance on a working memory task in the Morris water maze (MWM). However, acquisition of a reference memory task in the MWM was not improved. Serum analysis showed that the 500 mg/kg dose significantly raised nicotinamide concentrations by 30-fold and the 50 mg/kg dose by 3-fold compared to the saline administration. This study demonstrated that raising nicotinamide concentrations resulted in the reduction of the behavioral impairments following FPI. In fact, the 500 mg/kg dose prevented the occurrence of the behavioral deficits on the bilateral tactile removal and working memory tests. Both doses significantly reduced tissue loss and glial fibrillary acid protein (GFAP) expression in the cortex. The 500 mg/kg dose reduced GFAP expression in the hippocampus. This data suggests that nicotinamide has substantial preclinical efficacy for TBI, and there appears to be some differences in the ability of the doses to improve performance in the MWM.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 1535-1548 (14 pages)

Journal (Volume, Issue Number)

Journal of Neurotrauma (Volume 23, Issue 10)

Publication milestones

  • Published - 10/2006

Publication status

Published - 10/2006

ISSN

0897-7151

Publication IDs

  • Scopus: 33845230959
  • PubMed: 17020488

Publication metrics

Metrics

Fractional count
1
Fractional count
0.20
Fractional count
4
Fractional count
0.80
Fractional count
1
Fractional count
1
SciVal
citations
51
SciVal
FWCI
1.18
SciVal
Author count
5
SciVal
Paper percentile
88
Scopus
citations

PlumX, opens in new tab

Citation count
58
Captures
38

Funding Details

FunderFunding number
NINDS
R01NS041551